DEBIOTECH AND DELPHI IN PARTNERSHIP
FOR LAUSANNE, Switzerland. – DEBIOTECH SA announces license agreement with Delphi Medical Systems Corporation, a subsidiary of Delphi Corporation (NYSE: DPH). The licensing agreement includes rights to manufacture and market Debiotech’s ambulatory intravenous (IV) pump, its associated disposables and accessories. The license agreement includes upfront payments to Debiotech and royalties of an undisclosed amount. “We are delighted to enter into a close collaboration with one of the leading technology companies in the world, which has already contributed to some of the most significant developments in the automotive industry,” said President and CEO of Debiotech, Frederic Neftel. “This alliance adds tremendous potential to the medical device industry and we are extremely pleased to work toward novel therapeutic solutions in the infusion business together with Delphi Medical Systems”. Miniature and accurate, the dual battery-operated and AC-powered portable pump is lightweight, and small enough to be hand-held, making it ideal for use in homecare and alternate sites. The pump is designed to be easily clipped onto various accessories, such as IV poles and wheelchairs. It includes a shoulder strap and belt-clip for increased mobility, and could play an important role in hospitals, where it could be utilized for mobile in-patient care. In addition, the IV Pump includes state of the art remote IT programming and control capabilities which makes it particularly suitable for novel telemedicine healthcare. “We’re excited about this product and the new customer relationship opportunities it represents for our company,” said Christophe Sevrain, managing director of Delphi Medical Systems. “We are pleased to be entering into an agreement with a proven innovator like Debiotech, with an impressive track record of innovation in medical devices.” Having already received clearance from the Food and Drug Administration (FDA) and in compliance with the European Norm, CE, the patented pump and intravenous set will strategically add to Delphi Medical Systems’ product and technology portfolio. The IV Pump, which is already licensed and approved in Japan, will continue to be sold by JMS Corporation for the Japanese market. 
“Delphi Medical Systems is focused on being a provider of technology and manufacturing in the areas of dialysis, respiratory care, mobility, and infusion, of which this electronic pump is a key element,” Sevrain said. “We anticipate announcing strategic alliances with medical equipment manufacturers and distributors to further develop Delphi Medical Systems’ presence in the medical device market.” Capable of providing up-to-date technologies in circuit electronics, sensors, user-interface, wireless technologies, and more to address challenges in a global market, Delphi Medical Systems will provide components and complete medical instrumentation to medical equipment manufacturers and distributors. Debiotech S.A., specializes in the research and development of innovative medical devices in the field of drug delivery systems, electronic infusion systems, dialysis, diagnostics and imaging devices, drug eluting stents, implantable drug delivery systems and micro-systems for insulin and peptide drug delivery. For more information on Debiotech, please visit its website at: http://www.debiotech.com. For more information on Delphi, please visit its media room at: http:///www.delphi.com/media. Forward Looking Statement All statements contained or incorporated in this press release which address operating performance, events or developments that we expect or anticipate may occur in the future (including statements relating to future sales or earnings expectations, volume growth, awarded sales contracts or statements expressing general optimism about future operating results) are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are made on the basis of management’s current views and assumptions with respect to future events. Important factors, risks and uncertainties which may cause actual results to differ from those expressed in our forward-looking statements are discussed in detail in our filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2003. In particular, the achievement of projected levels of royalties and profit margins over a licensing agreement will depend in part on customer demand which may be affected by, among other things, uncertainty of product development and manufacturing, uncertainty about obtaining and maintaining FDA regulatory clearances and the timing of receiving marketing clearances, uncertainty relating to third party reimbursement, ability to convince health care professionals and third party payers of the medical and economic benefits of the licensed products, changes in general economic conditions, and changes in our ability to satisfy service, technology, quality and other requirements. Delphi does not intend or assume any obligation to update any of these forward-looking statements. # # #
Contact:
|